News Akeso, Inc.

Equities

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:14 17/03/2026 pm IST			5-day change	1st Jan Change
117.50 ^HKD	+0.77%		+13.31%	+3.98%

05/03	Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral	MT
05/03	Akeso, Inc. Presents Long-Term Phase II Results For Cadonilimab In Recurrent Or Metastatic Cervical Cancer	CI

All News

16/03	Akeso Announces Trispecific Antibody AK150 Enters Clinical Trials	CI
16/03	Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance	PR
05/03	INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma	AQ
05/03	Nomura Adjusts Akeso's Price Target to HK$112.73 From HK$120.64, Keeps at Neutral	MT
05/03	Akeso, Inc. Presents Long-Term Phase II Results For Cadonilimab In Recurrent Or Metastatic Cervical Cancer	CI
05/03	Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results	PR
04/03	INOVIO and Akeso Enter Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma	CI
04/03	Akeso and Inovio announce clinical collaboration to advance novel combination therapy for glioblastoma (gbm)	RE
04/03	Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)	PR
04/03	Inovio and Akeso announce clinical collaboration to advance novel combination therapy for glioblastoma (GBM)	RE
04/03	INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)	PR
11/02	Akeso, Inc.'s IL-4Ra/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications	CI
11/02	Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications	PR
06/02	Akeso, Inc. Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer	CI
06/02	Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer	PR
03/02	Akeso granted exclusive commercialization rights for ebronucimab injection to Jumpcan Pharmaceutical	RE
03/02	Akeso Grants Commercialization Rights for Hypercholesterolemia Drug to Hubei Jumpcan Pharmaceutical Unit	MT
30/01	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	AQ
29/01	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI
29/01	Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"	PR
19/01	Akeso, Inc. Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis	CI
19/01	Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis	PR
14/01	Akeso, Inc. Announces Presentation of Real-World Study At the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium	CI
14/01	Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer	PR
13/01	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	CI